Zum Hauptinhalt springen

Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha.

Paone, A ; Galli, R ; et al.
In: Neoplasia (New York, N.Y.), Jg. 12 (2010-07-01), Heft 7, S. 539-49
Online academicJournal

Titel:
Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha.
Autor/in / Beteiligte Person: Paone, A ; Galli, R ; Gabellini, C ; Lukashev, D ; Starace, D ; Gorlach, A ; De Cesaris, P ; Ziparo, E ; Del Bufalo, D ; Sitkovsky, MV ; Filippini, A ; Riccioli, A
Link:
Zeitschrift: Neoplasia (New York, N.Y.), Jg. 12 (2010-07-01), Heft 7, S. 539-49
Veröffentlichung: 2014- : [Amsterdam] : Elsevier ; <i>Original Publication</i>: New York, NY : Stockton Press, c1999-, 2010
Medientyp: academicJournal
ISSN: 1476-5586 (electronic)
DOI: 10.1593/neo.92106
Schlagwort:
  • Adenocarcinoma blood supply
  • Adenocarcinoma pathology
  • Apoptosis drug effects
  • Cell Hypoxia drug effects
  • Cell Hypoxia genetics
  • Cell Line, Tumor
  • Cells, Cultured
  • Gene Expression Regulation, Neoplastic drug effects
  • Gene Expression Regulation, Neoplastic physiology
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit metabolism
  • Male
  • Poly I-C pharmacology
  • Prostatic Neoplasms blood supply
  • Prostatic Neoplasms pathology
  • Toll-Like Receptor 3 agonists
  • Toll-Like Receptor 3 metabolism
  • Vascular Endothelial Growth Factor A genetics
  • Vascular Endothelial Growth Factor A metabolism
  • Adenocarcinoma genetics
  • Apoptosis genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit physiology
  • Neovascularization, Pathologic genetics
  • Prostatic Neoplasms genetics
  • Toll-Like Receptor 3 physiology
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • Language: English
  • [Neoplasia] 2010 Jul; Vol. 12 (7), pp. 539-49.
  • MeSH Terms: Adenocarcinoma / *genetics ; Apoptosis / *genetics ; Hypoxia-Inducible Factor 1, alpha Subunit / *physiology ; Neovascularization, Pathologic / *genetics ; Prostatic Neoplasms / *genetics ; Toll-Like Receptor 3 / *physiology ; Adenocarcinoma / blood supply ; Adenocarcinoma / pathology ; Apoptosis / drug effects ; Cell Hypoxia / drug effects ; Cell Hypoxia / genetics ; Cell Line, Tumor ; Cells, Cultured ; Gene Expression Regulation, Neoplastic / drug effects ; Gene Expression Regulation, Neoplastic / physiology ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit / genetics ; Hypoxia-Inducible Factor 1, alpha Subunit / metabolism ; Male ; Poly I-C / pharmacology ; Prostatic Neoplasms / blood supply ; Prostatic Neoplasms / pathology ; Toll-Like Receptor 3 / agonists ; Toll-Like Receptor 3 / metabolism ; Vascular Endothelial Growth Factor A / genetics ; Vascular Endothelial Growth Factor A / metabolism
  • References: Cell Biol Int. 2009 Feb;33(2):180-6. (PMID: 18996210) ; J Biol Chem. 2001 Dec 28;276(52):48754-63. (PMID: 11602577) ; Cancer Res. 1999 Nov 15;59(22):5830-5. (PMID: 10582706) ; Immunol Cell Biol. 2010 Feb;88(2):180-6. (PMID: 19841637) ; Cancer Res. 2006 Apr 1;66(7):3859-68. (PMID: 16585214) ; J Biol Chem. 2009 Apr 10;284(15):10004-12. (PMID: 19211554) ; J Biol Chem. 2006 Sep 8;281(36):25903-14. (PMID: 16847054) ; Cell Res. 2009 Aug;19(8):973-83. (PMID: 19381167) ; Nat Immunol. 2004 Jul;5(7):730-7. (PMID: 15208624) ; Carcinogenesis. 2008 Jul;29(7):1334-42. (PMID: 18566014) ; Neoplasia. 2008 Jul;10(7):674-9. (PMID: 18592007) ; Cancer Res. 2005 Jun 15;65(12):5009-14. (PMID: 15958541) ; J Immunol. 2006 Apr 15;176(8):4894-901. (PMID: 16585585) ; J Cell Sci. 2009 Apr 15;122(Pt 8):1055-7. (PMID: 19339544) ; Endocr Relat Cancer. 2006 Sep;13(3):739-49. (PMID: 16954428) ; J Interferon Res. 1993 Jun;13(3):241. (PMID: 7690057) ; J Immunol. 2008 Jul 15;181(2):1052-62. (PMID: 18606657) ; Vaccine. 2009 May 26;27(25-26):3401-4. (PMID: 19200817) ; Nat Immunol. 2004 Oct;5(10):987-95. (PMID: 15454922) ; J Leukoc Biol. 2009 Sep;86(3):681-9. (PMID: 19477908) ; Cell Mol Biol Lett. 2009;14(2):248-72. (PMID: 19096763) ; Mol Cells. 2009 Feb 28;27(2):243-50. (PMID: 19277508) ; Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):755-61. (PMID: 17272744) ; Nat Rev Cancer. 2002 Oct;2(10):795-803. (PMID: 12360282) ; Biol Reprod. 2004 Jul;71(1):331-9. (PMID: 15031145) ; Cancer Res. 1998 Dec 1;58(23):5280-4. (PMID: 9850048) ; Methods Enzymol. 2007;435:421-46. (PMID: 17998067) ; Blood. 2004 Feb 1;103(3):1124-30. (PMID: 14525767) ; Cancer Detect Prev. 2004;28(2):88-93. (PMID: 15068831) ; Curr Pharm Des. 2009;15(33):3844-52. (PMID: 19671046) ; Cancer Lett. 2006 Jun 8;237(1):10-21. (PMID: 16002209) ; Cell. 2006 Feb 24;124(4):783-801. (PMID: 16497588) ; J Clin Pathol. 2004 Oct;57(10):1009-14. (PMID: 15452150) ; Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4565-74. (PMID: 17671143) ; Genomics. 1998 Sep 1;52(2):159-65. (PMID: 9782081) ; J Biol Chem. 2005 Mar 11;280(10):9336-44. (PMID: 15611089) ; Urology. 2009 May;73(5 Suppl):S28-35. (PMID: 19375624) ; Blood. 1998 May 1;91(9):3471-80. (PMID: 9558407) ; Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5680-4. (PMID: 2062846) ; Cancer Metastasis Rev. 2007 Jun;26(2):341-52. (PMID: 17415529) ; J Clin Invest. 2009 May;119(5):1093-108. (PMID: 19363294) ; Oncogene. 2008 Jan 7;27(2):168-80. (PMID: 18176598) ; Sci STKE. 2005 Oct 18;2005(306):re12. (PMID: 16234508) ; Neoplasia. 2008 May;10(5):418-28. (PMID: 18472959) ; Hum Immunol. 2008 Jul;69(7):421-5. (PMID: 18638657) ; Neoplasia. 2009 Jul;11(7):615-28. (PMID: 19568407) ; Prostate. 2008 Sep 15;68(13):1405-15. (PMID: 18563715) ; Int J Biochem Cell Biol. 2005 Mar;37(3):535-40. (PMID: 15618010) ; Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10553-7. (PMID: 1961720) ; Biochem J. 2003 Mar 15;370(Pt 3):1011-7. (PMID: 12479793) ; Curr Med Chem. 2003 May;10(10):845-55. (PMID: 12678687) ; J Cell Mol Med. 2009 Sep;13(9A):2780-6. (PMID: 19674190) ; EMBO J. 1998 Sep 1;17(17):5085-94. (PMID: 9724644)
  • Grant Information: R21 AI068816 United States AI NIAID NIH HHS; R21 AI068816-01A1 United States AI NIAID NIH HHS
  • Substance Nomenclature: 0 (Hypoxia-Inducible Factor 1, alpha Subunit) ; 0 (TLR3 protein, human) ; 0 (Toll-Like Receptor 3) ; 0 (VEGFA protein, human) ; 0 (Vascular Endothelial Growth Factor A) ; O84C90HH2L (Poly I-C)
  • Entry Date(s): Date Created: 20100724 Date Completed: 20101105 Latest Revision: 20211020
  • Update Code: 20240513
  • PubMed Central ID: PMC2907580

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -